Tagrisso approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
Based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival by more than three years. AstraZeneca’s Tagrisso (osimertinib) has been approved in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy (CRT). Tagrisso is indicated for patients with exon 19 deletions or exon 21 (L858R) mutations, as detected by a FDA-approved test.